D8696
DMH4
>99.0% (HPLC)
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C24H24 N4O2
CAS Number:
Molecular Weight:
400.47
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
>99.0% (HPLC)
Form:
powder
Storage condition:
desiccated
assay
>99.0% (HPLC)
form
powder
storage condition
desiccated
color
off-white to brown
solubility
DMSO: 20 mg/mL
originator
Merck & Co., Inc., Kenilworth, NJ, U.S.
storage temp.
2-8°C
SMILES string
C1CN(CCO1)CCOc2ccc(cc2)-c3cnc4c(cnn4c3)-c5ccccc5
InChI
1S/C24H24N4O2/c1-2-4-20(5-3-1)23-17-26-28-18-21(16-25-24(23)28)19-6-8-22(9-7-19)30-15-12-27-10-13-29-14-11-27/h1-9,16-18H,10-15H2
InChI key
SKZQZGSPYYHTQG-UHFFFAOYSA-N
Biochem/physiol Actions
DMH4 is a potent VEGF inhibitor and an angiogenesis inhbitor. It is a selective VEGF inhibitor with an IC50 of 161 nM for VEGFR inhibition compared to 8000 nM for AMPK. Unlike the structurally similar DMH1, which is a selective BMP inhibitor, DMH4 shows little affinitiy for BMP with an IC50 of 3500 nM for BMPR-I.
DMH4 is a potent selective VEGF inhibitor; angiogenesis inhibitor.
Features and Benefits
This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
Discover Bioactive Small Molecules for Kinase Phosphatase Biology
Eric M Erkenbrack et al.
Journal of experimental zoology. Part B, Molecular and developmental evolution, 328(5), 423-432 (2017-05-26)
Comparative studies of early development in echinoderms are revealing the tempo and mode of alterations to developmental gene regulatory networks and to the cell types they specify. In euechinoid sea urchins, skeletogenic mesenchyme (SM) ingresses prior to gastrulation at the
Zaheer Ali et al.
Arteriosclerosis, thrombosis, and vascular biology, 39(7), 1402-1418 (2019-06-27)
Objective- Pathological neovascularization is crucial for progression and morbidity of serious diseases such as cancer, diabetic retinopathy, and age-related macular degeneration. While mechanisms of ongoing pathological neovascularization have been extensively studied, the initiating pathological vascular remodeling (PVR) events, which precede
Sungwoon Lee et al.
The Journal of clinical investigation, 127(2), 457-471 (2016-12-20)
Controlled angiogenesis and lymphangiogenesis are essential for tissue development, function, and repair. However, aberrant neovascularization is an essential pathogenic mechanism in many human diseases, including diseases involving tumor growth and survival. Here, we have demonstrated that mice deficient in C-type
Global Trade Item Number
| SKU | GTIN |
|---|---|
| D8696-5MG | 04061832961590 |
| D8696-25MG | 04061832270487 |